Rayzebio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Rayzebio Inc (RYZB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Rayzebio Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Rayzebio Inc | - | - | - | Yes |
| Competitors combined (78) | ||||
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RYZB Stock Performance relative to its Competitors
RYZB Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Omeros Corporation | 282.9% | Outperformed |
| 4 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 5 | Nurix Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Rayzebio Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Rayzebio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Rayzebio Inc | 962.34 | - |
| Bristol myers Squibb Company | 129,187.84 | 49,186.00 |
| Regeneron Pharmaceuticals Inc | 78,997.56 | 15,534.70 |
| Madrigal Pharmaceuticals Inc | 14,771.11 | 1,283.94 |
| Nuvalent Inc | 9,751.98 | 4.23 |
| Prometheus Biosciences Inc | 9,488.45 | 4.00 |
| SUBTOTAL | 304,351.04 | 70,595.17 |
Sign in to see all competitors of Rayzebio Inc .
Sources: Rayzebio Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Rayzebio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Rayzebio Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Qsam Biosciences Inc | Named by the company | 85% |
| Bristol myers Squibb Company | Named by the company | 85% |
| Fusion Pharmaceuticals Inc | Named by the company | 85% |
| Perspective Therapeutics Inc | Named by the company | 85% |
| Actinium Pharmaceuticals Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Rayzebio Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Rayzebio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
| Immunome Inc | Single reportable segment 100.00 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Rayzebio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Rayzebio Inc | 962 | - | - |
| Bristol myers Squibb Company | 129,188 | 1,513,415 | 285,354 |
| Regeneron Pharmaceuticals Inc | 78,998 | 1,008,092 | 280,902 |
| Madrigal Pharmaceuticals Inc | 14,771 | 1,403,213 | -355,295 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Prometheus Biosciences Inc | 9,488 | 27,937 | -1,052,881 |
| PEERS TOTAL | 303,389 | 1,167,345 | 115,982 |
Rayzebio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bristol myers Squibb Company | United States 67.79 % |
| Novavax inc | United States 68.88 % |
| Opko Health Inc | US 54.29 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Rayzebio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-12.1% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Rayzebio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Rayzebio Inc | - | - | - |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Madrigal Pharmaceuticals Inc | 0.72 | 3.52 | 0.60 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Prometheus Biosciences Inc | 7.04 | 23.30 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Rayzebio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Rayzebio Inc | Q3 2023 | - | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | +71.2 % | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Prometheus Biosciences Inc | Q1 2023 | -71.8 % | - |
| PEERS TOTAL | +8.6 % | +123.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Rayzebio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Rayzebio Inc | Q3 2023 | - | - |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | - | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Prometheus Biosciences Inc | Q1 2023 | - | - |
Rayzebio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Rayzebio Inc | - | - | - |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Nuvalent Inc | - | - | - |
| Prometheus Biosciences Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Rayzebio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Rayzebio Inc | - | - |
| Bristol myers Squibb Company | 13.89 | 2.63 |
| Regeneron Pharmaceuticals Inc | 18.46 | 5.09 |
| Madrigal Pharmaceuticals Inc | - | 11.50 |
| Nuvalent Inc | - | 2,303.80 |
| Prometheus Biosciences Inc | - | 2,375.08 |
| PEERS AVERAGE | 43.39 | 4.31 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.